Spero Therapeutics, Inc.
Income Statement
| Line Item | Aug 2026 | Jun 2026 | May 2026 | Mar 2026 | Mar 2026 | Dec 2025 | Nov 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $0 | — | $258.0K | — | — | — | $5.4M |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | $3.4M | — | $2.9M | — | — | — | $8.6M |
| SG&A Expense | — | $6.5M | — | $4.9M | — | — | — | $4.2M |
| Operating Income | — | $-9.9M | — | $-7.5M | — | — | — | $-7.9M |
| Operating Margin | — | — | — | -2,921.7% | — | — | — | -145.5% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | — | — | — | — | — | — | — | $0 |
| Net Income | — | $-9.6M | — | $-7.2M | — | — | — | $-7.4M |
| Net Margin | — | — | — | -2,791.9% | — | — | — | -135.6% |
| EPS (Basic) | — | $-0.16 | — | $-0.13 | — | — | — | $-0.13 |
| EPS (Diluted) | — | $-0.16 | — | $-0.13 | — | — | — | $-0.13 |
| Shares Outstanding (Basic) | 58.2M | 58.0M | 57.9M | 57.3M | 57.9M | 56.4M | 56.3M | 56.3M |
| Shares Outstanding (Diluted) | 58.2M | 58.0M | 57.9M | 57.3M | 57.9M | 56.4M | 56.3M | 56.3M |
| Dividends Per Share | — | — | — | — | — | — | — | — |